Monsanto, Nomad Bioscience Announce Collaboration
News Jun 29, 2016
The licensed technology enables more efficient development of edited traits and may be applied across a broad range of genome-editing technologies and project types. Nomad’s novel approach holds the promise to accelerate the development of improved agricultural products via genome editing.
“Our approach greatly increases both the efficiency of genome editing and the ability to deploy edited traits in commercial varieties, which could prove to be beneficial to the speed and scale at which potential products are developed,” said Dr. Yuri Gleba, chief executive officer and Nomad founder.
The agreement includes a three-year research project, during which scientists at Nomad will continue to expand the applicability of their technology. In addition, the agreement provides Monsanto with rights to use Nomad’s technology for research projects during the term, as well as an option for an exclusive commercial license to apply the proprietary technology in the development of agriculture products. Additional details of the agreement were not disclosed.
“Monsanto is committed to delivering best-in-class solutions to growers who face increasing challenges every year,” said Tom Adams, biotechnology lead for Monsanto. “Our collaboration with Nomad is one example of how we employ the industry’s best science through our own R&D pipeline and through strategic partnerships to continually drive agriculture innovation.”
Gene-editing technologies offer a way for scientists to develop site-directed integration of specific genes as well as the opportunity to enhance beneficial or remove undesired plant characteristics. Monsanto believes that genome-editing technologies will enable plant breeders to deliver better hybrids and varieties more efficiently, as well as offer plant scientists additional resources to deliver new improvements in plant biotechnology.
Nomad is a privately-held biotechnology company headquartered in Munich, Germany.
Gene-edited Organoids Reveal How Deadly Brain Cancer GrowsNews
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers. Researchers have now taken an important step towards meeting that challenge.READ MORE
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE